Indonesian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Halaman 1 dari 119 hasil
Fatigue in patients with low grade glioma: systematic evaluation of assessment and prevalence.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Fatigue is the most prevalent and disabling symptom in cancer patients. Yet, scientific literature on this topic is scarce and reports disparate results. This study systematically reviews how fatigue is assessed in patients with low-grade glioma and evaluates its prevalence in LGG patients. A
Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Diffuse intrinsic pontine glioma (DIPG) is an incurable disease with a median overall survival of 10 months. Immune modulating antibodies have recently emerged as a highly promising treatment modality in multiple cancer types. We present results from the first study to evaluate the immune modulating
A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Preclinical activity of irinotecan has been seen in glioma models, but only modest efficacy has been noted in clinical studies, perhaps related to drug distribution and/or pharmacokinetic limitations. In preclinical testing, irinotecan liposome injection (nal-IRI) results in prolongation of drug
Prospective study of quality of life in adults with newly diagnosed high-grade gliomas.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
OBJECTIVE
To assess baseline quality of life (QOL) and its prognostic importance for adults with newly diagnosed high-grade gliomas, we analyzed QOL and outcome data prospectively collected in three phase II high-grade glioma protocols.
METHODS
At study entry, patients completed five
A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
OBJECTIVE
To determine the response rate, time to disease progression, survival, and toxicity of intravenous carboplatin and chronic oral high-dose tamoxifen in patients with recurrent malignant gliomas.
METHODS
Patients with histological confirmation of recurrent malignant gliomas were eligible for
Intra-arterial bromodeoxyuridine radiosensitization of malignant gliomas.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
In the 1950's it was first observed that mammalian cells exposed to the halogenated deoxyuridines were more sensitive to ultraviolet light and radiation than untreated cells. This prompted early clinical trials with bromodeoxyuridine (BUdR) which showed mixed results. More recently, several Phase I
Bevacizumab use for recurrent high-grade glioma at McGill University Hospital.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
BACKGROUND
Bevacizumab, a humanized recombinant anti-vascular endothelial growth factor antibody, was approved in Canada in 2010 for the treatment of high-grade glioma. We report the effectiveness and safety of bevacizumab in the treatment of patients with recurrent high-grade gliomas at a single
The ocular effects of intracarotid bromodeoxyuridine and radiation therapy in the treatment of malignant glioma.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Since July 1985, 23 patients have been entered into a phase I/II clinical trial using intraarterial 5-bromodeoxyuridine (BUdR) (400-600 mg/m2 daily for 8.5 weeks) and focal external beam radiotherapy (59.4 Gy at 1.8 Gy daily in 6.5 weeks) in the treatment of malignant gliomas (Kernohan grades 3 and
Palliative reirradiation for progressive diffuse intrinsic pontine glioma.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
OBJECTIVE
Diffuse intrinsic pontine gliomas (DIPGs) are highly aggressive tumors and have a poor prognosis. Nearly all patients experience disease progression after definitive treatment, accompanied by severe neurologic deficits and morbidity. Here, we report a series of patients treated with
[Coping in patients with malignant glioma in the course of radiation therapy].
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
Twenty-one patients with malignant glioma were interviewed in the course of radiation therapy (before start, in the middle and at the end of treatment and six weeks later). We used the "Freiburger Fragebogen zur Krankheitsverarbeitung (FKV)", an assessment of coping strategies, the
Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
OBJECTIVE
To determine the maximum-tolerated dose (MTD) of paclitaxel administered as a 3-hour infusion in patients with recurrent malignant glioma.
METHODS
Patients were stratified by starting dose of paclitaxel and concurrent anticonvulsant (AC) use and were treated in cohorts of three patients.
Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
We determined the maximum tolerated dose (MTD), toxicity profile, pharmacokinetic parameters, and preliminary efficacy data of oral sodium phenylbutyrate (PB) in patients with recurrent malignant gliomas. Twenty-three patients with supratentorial recurrent malignant gliomas were enrolled on this
A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
This phase II study in recurrent high-grade glioma evaluated the response rate, toxicities, and time to treatment failure of high-dose carboplatin modulated by a 24-h infusion of thymidine (75 g/m(2)). The trial was based on preclinical data and a prior phase I study ( J. Clin. Oncol. 17, 2922-2931,
Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
OBJECTIVE
To determine the response rate, time to treatment failure, and toxicity of phenylacetate in patients with recurrent malignant glioma and to identify plasma concentrations achieved during repeated continuous infusion of this agent.
METHODS
Adult patients with recurrent malignant glioma were
First experiences in treatment of low-grade glioma grade I and II with proton therapy.
Hanya pengguna terdaftar yang dapat menerjemahkan artikel
Masuk daftar
BACKGROUND
To retrospectively assess feasibility and toxicity of proton therapy in patients with low-grade glioma (WHO °I/II).
METHODS
Proton beam therapy only administered in 19 patients (median age 29 years; 9 female, 10 male) for low-grade glioma between 2010 and 2011 was reviewed. In 6 cases
Database tanaman obat terlengkap yang didukung oleh sains
- Bekerja dalam 55 bahasa
- Pengobatan herbal didukung oleh sains
- Pengenalan herbal melalui gambar
- Peta GPS interaktif - beri tag herba di lokasi (segera hadir)
- Baca publikasi ilmiah yang terkait dengan pencarian Anda
- Cari tanaman obat berdasarkan efeknya
- Atur minat Anda dan ikuti perkembangan berita, uji klinis, dan paten
Ketikkan gejala atau penyakit dan baca tentang jamu yang mungkin membantu, ketik jamu dan lihat penyakit dan gejala yang digunakan untuk melawannya.
* Semua informasi didasarkan pada penelitian ilmiah yang dipublikasikan
